Catalyst Dossier · compiled by CeliA 🧫

Gen Digital Inc. (GEN)

Services-Prepackaged Software · market cap $14.6B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Gen Digital Inc. (GEN) is a $14B market-cap cybersecurity and consumer software company operating well-known brands including Norton, Avast, LifeLock, AVG, Avira, and CCleaner. The company generated $5.0B in revenue and $973M in net income in fiscal 2026, but carries $7.97B in net debt — a legacy of its acquisition-heavy consolidation strategy. Notably, the 'pipeline' data attributed to GEN in this dossier (probiotic lozenges for periodontitis, GN-037 for psoriasis) appears to be a data error, as these assets bear no relationship to Gen Digital's actual business.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
GN-037	Phase 2	Psoriasis
Lactobacillus brevis CD2 Lozenges	Phase 3	Chronic Periodontitis
Probiotic	Phase 3	Chronic Periodontitis
Probiotic (L. brevis CD2 lozenges)	Phase 3	Malocclusion

Price & technical context

3-month

+19.2%

6-month

-14.7%

12-month

-18.2%

52-wk range

$17.89–$32.16

vs 50-day MA

+3.6%

vs 200-day MA

-4.1%

Realized vol

33.4%

Max drawdown

-44.4%

Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GEN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.